Katharina Stölzel (Hamburg), Daniella Drabek (Hamburg), Christian Betz (Hamburg), Henrike Zech (Hamburg)
Introduction: Malignancies of the nasal cavity and paranasal sinuses constitute a heterogeneous group of various entities, with squamous cell carcinomas being the largest subgroup. Due to the rarity of these tumors, there is a lack of clinical studies. Registry studies can contribute to a better understanding of this entity.
Method: The clinical data of patients with SNSCC treated at the University Medical Center Hamburg-Eppendorf from 2009 to 2022 were retrospectively analyzed.
Results: From 2009 to 2022, 70 patients with SNSCC were treated. There was no significant increased incidence over time. The average age of patients was 62.5 years and male to female ratio 3:1. 9 patients had a second carcinoma, 5 in the head and neck area. Symptoms were variable, most common nose bleeding and nasal obstruction. Time from onset of symptoms to diagnosis was 8,8 months. 22 patients were in UICC stadium I, 16 in II, 7 in III and 25 in IVA. Most patients were treated with surgery (88,8%) adjuvant radiotherapy (18%) or radiochemotherapy (43%), only few were classified as non-operable and received induction chemotherapy or primary radiochemotherapy. At time of diagnosis 5 patients showed lymph node metastasis and 1 patient pulmonary metastasis. Lymph node metastasis appearance correlated with T-stadium. 25 patients faced locoregional recurrence, on average 11,5 months after primary therapy (range: 3 – 51 months) and 14 patients showed distant metastasis, on average 10 months after therapy (range: 2 – 33).
Conclusion: SNSCC are a rare entity showing dismal prognosis. Most patients are in curative state at time of diagnosis, the prevalence of locoregional and distant metastasis highlights the pressing need for more effective treatments for this condition.
Es besteht kein Interessenkonflikt